Keyphrases
Remote Monitoring Technology
80%
New Platform
80%
Telemonitoring Technology
53%
Usability Testing
40%
Cancer Patients
40%
Web Services
40%
Cell Phone
40%
Ambulatory Setting
26%
User Demographics
26%
Behavioral Informatics
26%
Narrow Therapeutic Index
26%
Non-adherence
26%
All-solution-processed
26%
RandD
26%
Adherence Rate
26%
Chronic Cancer
26%
Medication Compliance
26%
Randomized Controlled Study
26%
Oral Chemotherapeutic
26%
Wireless Platform
26%
Clinically Meaningful Improvement
26%
Interface Services
26%
Communication Strategies
26%
Web Service Interface
26%
Radio Frequency Identification
26%
Web User Interface
26%
Medication Nonadherence
26%
Socio-demographic Groups
26%
Apple iPhone
26%
Pharmaceutical Supply Chain
26%
Lifestyle-related Disease
26%
Functional Prototype
26%
Informatics Research
26%
Network Appliance
26%
Severe Toxicity
26%
Promising Technology
26%
Platform-Based
19%
One-size-fits-all
19%
Health Problems
19%
User-centered
19%
Patient-Reported Outcomes Measurement Information System (PROMIS)
19%
Chronic Patients
19%
Smartphone
19%
National Institute on Aging
19%
Research-clinical
19%
Small Business Innovation Research
19%
Healthcare
19%
Medication Adherence
19%
Health Informatics
19%
Technical Feasibility
19%
Drug-related Problems
19%
Health Systems
19%
Healthcare Expenditure
19%
Widespread Adoption
19%
National Cancer Institute
19%
Clinical Trials
19%
Research Laboratories
19%
Research nurse
19%
Patient Care
19%
Disease States
19%
Existing Technology
19%
Medication Use
19%
Self-efficacy
19%
Communication Platform
19%
Telemonitoring
5%
Assisted Care
5%
Doctor Visits
5%
Clinical Self-efficacy
5%
Early Admission
5%
Computer Science
Cancer Patient
100%
Remote Monitoring
100%
Web Service
73%
Communication Strategies
53%
Disease Patient
53%
Business Innovation
46%
Personal Digital Assistant
46%
Web Service Interface
46%
Web User Interface
46%
Pharmaceutical Supply Chain
46%
Radio Frequency Identification
46%
Widespread Adoption
43%
Health Care
43%
Cell Phone
36%
Small Business
36%
Technical Feasibility
36%
And-States
36%
Disease Progression
6%